Search clinical trials for: MPS I

Total 495137 results

Novartis

Completed

Conversion Trial From Mycophenolate Mofetil (MMF) to Enteric-coated Mycophenolate Sodium (EC-MPS) in Stable Transplanted Patients Suffering From Gastrointestinal (GI) Adverse Events While on Mycophenolate Mofetil Therapy (MMF) Therapy

Liver Transplantation | Kidney Transplantation

Switzerland
Genentech, Inc.

Completed

A Phase II Study of the Safety and Efficacy of MPSK3169A in Patients With Coronary Heart Disease or High Risk of Coronary Heart Disease

Coronary Heart Disease

United States, New Zealand, Germany, Canada, Slovakia, Hungary, Norway, South Africa, Czech Republic
Centre Hospitalier Universitaire Dijon

Completed

Efficacy of Heat-shock Protein (HSP) Inhibitors in Myeloproliferative Syndromes (MPS) (HSP-SMP)

Myeloproliferative Syndrome

France
Epstein, Arthur B., OD, FAAO
Alcon Research

Completed

Study of the Presence and Extent of Corneal Disturbance Associated With B+L Biotrue MPS Used With B+L PureVision Lenses

Keratitis

United States
Alexion Pharmaceuticals

Completed

Evaluation of Blood Brain Barrier Integrity and Structural Abnormalities in MPS IIIB Patients Using Multimodal Magnetic Resonance Imaging

MPS IIIB (Sanfilippo B Syndrome)

United Kingdom
Novartis Pharmaceuticals

Completed

A National Multi-center Randomized, Open Label Study to Evaluate Efficacy and Safety of Everolimus With EC-MPS Compared to Standard Treatment Combination Tacrolimus and EC-MPS in de Novo Liver Transplant Recipients (SIMCER)

Liver Transplantation

France
Novartis Pharmaceuticals

Completed

Measurement of Patient Reported Outcomes in Renal Transplant Patients With And Without Gastrointestinal (GI) Symptoms (PROGIS)

Kidney Transplantation | GI Symptoms Severity

Malaysia
University of California, Los Angeles
Novartis

Completed

Small Bowel Capsule Endoscopy Findings in Patients Receiving Cellcept®

Signs and Symptoms, Digestive | Gastrointestinal Lesions

United States
BioMarin Pharmaceutical

Terminated

Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome

Morquio A Syndrome | MPS IVA | Mucopolysaccharidosis IVA

United States, United Kingdom, Canada, Germany
Patricia I. Dickson, M.D.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University... and other collaborators

Completed

A Study of Intrathecal Enzyme Therapy for Cognitive Decline in MPS I

Mucopolysaccharidosis I | Scheie Syndrome | Lysosomal Storage Disease | Cognitive Decline | Hurler-Scheie Syndrome

United States
BioMarin Pharmaceutical

Terminated

Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation

Morquio A Syndrome | MPS IVA | Mucopolysaccharidosis IVA

United Kingdom, United States, Germany
Nationwide Children's Hospital
Sanfilippo Children's Research Foundation; The Sanfilippo Research Foundation; The Children's Medical Research Foundation

Completed

Natural History Studies of Mucopolysaccharidosis III

Mucopolysaccharidosis Type IIIA | Mucopolysaccharidosis Type IIIB

United States
Abbott Medical Optics

Completed

Comparative Evaluation of Corneal Staining With Balafilcon A Lenses and Two Multi-Purpose Solutions

Astigmatism | Myopia | Hyperopia

United States
BioMarin Pharmaceutical

Terminated

A Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)

Morquio A Syndrome | MPS IV A | Mucopolysaccharidosis IVA

United Kingdom
Hoffmann-La Roche

Completed

A Pharmacokinetic Study of CellCept (Mycophenolate Mofetil) Versus Mycophenolate Sodium in Kidney Transplant Patients

Kidney Transplantation

Germany
Cancer Advances Inc.
Clinical Project Services; MPS Research Unit

Completed

Dose-ranging Study to Evaluate Antibody Response to G17DT in Patients With Gastric Cancer

Gastric Cancer
Greenwood Genetic Center
Shriners Hospitals for Children; BioMarin Pharmaceutical

Completed

Screening an Orthopedic Population for Mildly-affected Individuals With Morquio Syndrome A and Maroteaux-Lamy Syndrome

MPS IVA | Maroteaux Lamy Syndrome | MPS VI | Morquio Syndrome A

United States
Children's Hospitals and Clinics of Minnesota
BioMarin Pharmaceutical; Gillette Children's Specialty Healthcare; Greenwood...

Completed

Diagnosis of Mucopolysaccharidosis Disorders in Patients Presenting With Bilateral Hip Disease

Mucopolysaccharidosis VI | Mucopolysaccharidosis IV A

United States
Montefiore Medical Center
Albert Einstein College of Medicine

Terminated

Study Comparing CT Scan and Stress Test in Patients With Known Coronary Artery Disease Hospitalized for Chest Pain (PROSPECT-CAD)

Coronary Artery Disease | Angina Pectoris | Acute Coronary Syndrome | Unstable Angina

United States
Genzyme, a Sanofi Company
BioMarin/Genzyme LLC

Completed

Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I

Mucopolysaccharidosis I | Hurler-Scheie Syndrome | Hurlers Syndrome

United States, Canada, Germany
Irmandade Santa Casa de Misericórdia de Porto Alegre
Novartis

Completed

A Prospective Study to Investigate Mycophenolic Acid (MPA) Exposure Through Area Under the Curve (AUC) in Renal Transplants Recipients Treated With Mycophenolate Mofetil (MMF) and After Conversion to Mycophenolate Sodium (EC-MPS) (AUC-MPA)

Renal Transplantation

Brazil
Genzyme, a Sanofi Company
BioMarin/Genzyme LLC

Completed

A Study Evaluating the Safety and Pharmacokinetics of Aldurazyme® (Laronidase) in MPS I Patients Less Than 5 Years Old

Mucopolysaccharidosis I | Scheie Syndrome | Hurler Syndrome | Hurler-Scheie Syndrome

Netherlands, France, Germany, United Kingdom
Genzyme, a Sanofi Company
BioMarin/Genzyme LLC

Completed

Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients

Mucopolysaccharidosis I | Scheie Syndrome | Hurler's Syndrome | Hurler-Scheie Syndrome

United States, Canada, United Kingdom, Brazil, Germany, Italy, Netherlands
Genzyme, a Sanofi Company
BioMarin/Genzyme LLC

Completed

A Dose-optimization Study of Aldurazyme® (Laronidase) in Patients With Mucopolysaccharidosis I (MPS I) Disease

Mucopolysaccharidosis I | Scheie Syndrome | Hurler's Syndrome | Hurler-Scheie Syndrome

Brazil, Canada
National Institute of Allergy and Infectious Diseases...

Completed

Leprosy Skin Test Antigens Trial

Leprosy

Nepal, United States
Nestlé

Completed

Daily Protein Intake Distribution and MPS (ARCIII)

Overweight
BioMarin Pharmaceutical

Terminated

A Clinical Assessment Study of Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome)

Morquio A Syndrome | MPS IV A | Mucopolysaccharidosis IVA

France, United Kingdom, Taiwan, United States, Argentina, Netherlands, Canada, Brazil, Germany, Italy
Novartis Pharmaceuticals

Completed

Multicenter, Randomized, Open-label Study to Assess Whether Treatment With Mycophenolate Sodium (MPS) Allows Higher Dose Optimization Versus Mycophenolate Mofetil (MMF) Leading to a Dose Reduction of Tacrolimus. Maximiza Study. (MAXIMIZA)

Prophilaxis of Acute Rejection in Patients Receiving a Renal Allograft

Spain
Chulalongkorn University
Clinical Research Collaborative Network; Health Intervention and Technology...

Terminated

The Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) (Myfortic) in The Treatment of Relapse or Resistant Proliferative Lupus Nephritis (CONTROL)

Lupus Nephritis

Thailand
UCB Pharma

Completed

Efficacy, Safety and Tolerability of Rotigotine Nasal Spray for the Acute Treatment of Parkinson Symptoms

Parkinson's Disease
UCB Pharma

Completed

An Open-Label Follow-on Trial to Assess the Long-Term Safety and Efficacy of Oral SPM 927 in Subjects With Postherpetic Neuralgia (PHN)

Postherpetic Neuralgia

Germany
UCB Pharma

Completed

A Trial to Assess the Efficacy and Safety of SPM 927 (Lacosamide) in Subjects With Painful Distal Diabetic Neuropathy

Diabetic Neuropathy

Germany
UCB Pharma

Completed

Trial to Assess the Efficacy and Safety of SPM 927 (200, 400, and 600mg/Day) in Subjects With Painful Distal Diabetic Neuropathy

Diabetic Neuropathies

United States
UCB Pharma

Completed

Safety and Tolerability of Intravenous SPM 927 as Replacement for Oral SPM 927 in Subjects With Partial Seizures

Epilepsies, Partial

United States
UCB Pharma

Completed

A Trial to Assess the Efficacy and Safety of SPM 927 in Subjects With Painful Distal Diabetic Neuropathy

Diabetic Neuropathy

United States
UCB Pharma

Completed

A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Trial to Investigate the Efficacy and Safety of SPM 927 (200mg/Day and 400mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization

Partial Seizures With or Without Secondary Generalization

Germany
UCB Pharma

Completed

SPM 927 (400mg/Day and 600mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization

Epilepsy
Nanfang Hospital of Southern Medical University
Peking University People's Hospital; Sun Yat-sen University; Guangzhou First... and other collaborators

Unknown

Megakaryocytic Progenitor Cells for Prophylaxis and Treatment of Thrombocytopenia

Thrombocytopenia | Hematological Diseases

China
Emory University
BioMarin Pharmaceutical

Terminated

Discovering New Biomarkers For Monitoring Disease Progression in Patients With Mucopolysaccharidosis IVA

Mucopolysaccharidosis Type IVA

United States
Novartis Pharmaceuticals

Terminated

Comparison of CNI-based Regimen Versus CNI-free Regimen in Kidney Transplant Recipients.

Renal Transplantation

Germany
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant Recipients

Chronic Renal Failure

Israel
Novartis Pharmaceuticals

Completed

Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant Recipients

Renal Function

Denmark, Norway, Sweden
Duke University

Completed

Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders

Hemoglobinopathies | Thalassemia | Lysosomal Storage Disease | Immunodeficiencies | Inborn Errors of Metabolism | Sickle Cell | Non Malignant Disorders | Congenital Marrow Failures

United States
National Institute of Allergy and Infectious Diseases...

Completed

Leprosy Skin Test Antigens Phase 1

Leprosy
Alcon Research

Completed

An Evaluation of Marketed Contact Lens Disinfectant Systems on Eyelid Tissues (ID11-56)

Myopia
Alcon Research

Completed

Silicone Hydrogel Contact Lens Clinical and Comfort Benefits With a Multi-Purpose Disinfecting Solution

Refractive Error | Presbyopia | Astigmatism | Myopia | Hyperopia
Aldagen

Terminated

ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases (UCBT-002)

Mucopolysaccharidosis | Inborn Errors of Metabolism | Lysosomal Storage Disorders | Inherited Metabolic Diseases | Peroxisomal Storage Diseases

United States
BioMarin Pharmaceutical

Completed

A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)

MPS IV A

United States, Canada, France, United Kingdom, Taiwan, Argentina, Colombia, Japan, Saudi Arabia, Netherlands, Denmark, Korea, Republic of, Brazil, Germany, Portugal, Italy, Qatar
Genzyme, a Sanofi Company
BioMarin/Genzyme LLC

Completed

Immune Tolerance Study With Aldurazyme® (Laronidase)

Mucopolysaccharidosis I

Brazil, Russian Federation
BioMarin Pharmaceutical

Completed

A Study to Evaluate the Safety, Tolerability and Efficacy of BMN 110 in Subjects With Mucopolysaccharidosis IVA

MPS IV A

United Kingdom

Search clinical trials for: MPS I

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Canada

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations